Tackling the New Bottleneck of Drug Discovery
In This Episode
The 'Life Sciences DNA' Podcast, sponsored by Agilisium Labs, dives deep into groundbreaking innovations at the crossroads of technology and life sciences. In this episode, host Dr. Amar Drawid sits down with Markus, Chief Scientific Officer and Co-founder of Synthace, a leader in transforming research and development through advanced digital experimentation.
- Explore how AI is revolutionizing drug discovery and development.
- Learn from Markus's comparison of AI’s impact to the electrification of factories.
- Discover how machine learning, deep learning, automation, and generative AI are transforming R&D.
- Understand how AI improves experimental design, automates workflows, and enhances data analysis.
- Examine AI’s role in accelerating therapeutic discovery and advancing personalized medicine.
Our Host
Dr. Amar Drawid
Dr. Amar Drawid, an industry veteran who has worked in data science leadership with top biopharmaceutical companies. He explores the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.
Our Speaker
Dr. Markus Gershater
Markus Gershater is the Chief Scientific Officer and co-founder of Synthace, a company pioneering the integration of digital technology into the experimental research process. With a PhD in plant biochemistry from Durham University, Markus has a deep understanding of biological complexity and how to effectively address it to engineer biology and biological processes. His expertise spans robust, transferable protocols, flexible automation, and sophisticated experimental design and data analysis.
.png)
.png)
.png)
.png)
